This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
SUMMARY
- Johnson & Johnson does not recommend the use of TALVEY in a manner that is inconsistent with the approved labeling.
- This response provides relevant data from company-sponsored clinical trials, and the content is limited to the studies included below.
- Please refer to local labeling for recommended pre-treatment medications to reduce the risk of cytokine release syndrome (CRS) and CRS management recommendations.
- Consider further management per current practice guidelines or institutional guidelines.
- MonumenTAL-1 is an ongoing, open-label, phase 1/2 study evaluating the efficacy and safety of TALVEY in patients with relapsed or refractory multiple myeloma (RRMM) after ≥3 prior lines of therapy (LOTs), including a proteasome inhibitor (PI), an immunomodulatory drug, and an anti-CD38 monoclonal antibody (mAb).1,2
- Perrot et al (2026)3 presented the impact of prophylactic tocilizumab (8 mg/kg intravenous [IV]) on the efficacy, safety, and CRS parameters in patients who received 1 or 2 step-up doses (SUDs) prior to TALVEY every other week (Q2W) treatment at a median follow-up of 6.2 months (range, 1.6-11.3).
- Morillo et al (2024)4 presented the impact of fewer SUDs of TALVEY (0.8 mg/kg Q2W) on the efficacy, safety, and CRS parameters in alternative TALVEY Q2W SUD (n=6, group 1; n=12, group 2) and global (N=154) Q2W TALVEY cohorts at a median follow-up of 6.7 months (range, 2.2-9.9).
CLINICAL DATA - Monumental-1 Study
MonumenTAL-1 (NCT03399799, NCT04634552) is a phase 1/2 study of TALVEY in patients with RRMM.1,2
Study Design/Methods (Phase 2)
Patients were enrolled into 1 of the following 3 cohorts5,6:
- T-cell redirection (TCR)-naïve: 0.4 mg/kg subcutaneous (SC) weekly (QW), not previously exposed to TCR therapies such as chimeric antigen receptor-modified T-cell (CAR-T) therapy or bispecific antibodies (prior exposure to B-cell maturation antigen [BCMA] antibody-drug conjugate [ADC] allowed).
- TCR-naïve: 0.8 mg/kg SC Q2W, not previously exposed to TCRs (prior exposure to BCMA ADC allowed).
- Prior TCR: 0.4 mg/kg SC QW or 0.8 mg/kg SC Q2W, have been previously exposed to TCRs.
- Among the prior TCR-exposed cohort, patients were divided based on the type of TCR (CAR-T, BsAb, or CAR-T and BsAb).
- Key eligibility criteria1:
- ≥18 years of age, measurable multiple myeloma (MM) per International Myeloma Working Group (IMWG) criteria.
- ≥3 prior LOTs including a PI, an immunomodulatory drug, and an anti-CD38 mAb.
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2.
- Primary endpoint: overall response rate (ORR).5
- Key secondary endpoints: duration of response (DOR), progression-free survival (PFS), overall survival, safety, immunogenicity, and pharmacodynamics.5
- Dosing
- SUDs of TALVEY were administered as follows1:
- 0.4 mg/kg SC QW: 0.01 mg/kg, and 0.06 mg/kg.
- 0.8 mg/kg SC Q2W: 0.01 mg/kg, 0.06 mg/kg, and 0.3 mg/kg.
- Subsequent treatment doses: 0.4 mg/kg SC QW or 0.8 mg/kg SC Q2W until disease progression, unacceptable toxic effects, withdrawal of consent, or end of study.1
- Premedications: glucocorticoid (dexamethasone 16 mg or equivalent), antihistamine, and antipyretic were required to be administered for each SUD, and for the first full treatment dose of TALVEY.1
- Patients were required to be hospitalized for at least 48 hours from the start of each SUD and the first full treatment dose of TALVEY.1
Perrot et al (2026)3 presented the impact of prophylactic tocilizumab (8mg/kg IV) on efficacy, safety, and CRS parameters in patients who received 1 or 2 SUDs prior to TALVEY Q2W treatment at a median follow-up of 6.2 months (range, 1.6-11.3). The evaluated step-up dosing regimens comprised 1 SUD (0.4 mg/kg; n=10 [inpatient]) or 2 SUDs (0.06 and 0.4 mg/kg; n=20 [10 inpatient, 10 outpatient]).
Methods
- Key eligibility criteria3:
- RRMM from phase 2 of MonumenTAL-1.
- ≥1 prior LOT; ≥1 PI, ≥1 immunomodulatory drug, and ≥1 anti-CD38 mAb.
- Dosing3:
- Prophylactic tocilizumab 8 mg/kg IV was administered approximately 3 hours prior to TALVEY with required pretreatments (glucocorticoid, antihistamine, and antipyretic).
- Alternative TALVEY step-up dosing regimens in cohort E included 1 SUD (0.4 mg/kg SC) and 2 SUDs (0.06 mg/kg and 0.4 mg/kg SC).
- Patients subsequently received TALVEY 0.8 mg/kg SC Q2W.
- SUDs were administered 2 to 4 days apart, and the first full TALVEY treatment dose was administered 2 to 9 days after the last SUD.
- The first 10 patients in each SUD regimen received the SUD and first full treatment dose in an inpatient setting; subsequent patients were treated in the outpatient setting.
- Patients and caregivers in the outpatient setting were informed of the signs and symptoms of CRS, immune effector cell-associated neurotoxicity syndrome (ICANS), infections, and other adverse events (AEs). They were instructed to monitor body temperature twice daily (≥8 hours apart) for 48 hours following each SUD and the first full treatment dose.
Results
Treatment Disposition, Baseline Demographics, and Disease Characteristics
MonumenTAL-1 Study (Cohort E): Baseline Characteristics3
|
|
|---|
Median follow-up, months (range)
| 6.2 (1.6-11.3)
|
Median age, years (range)
| 65.5 (49-81)
|
White, n (%)
| 29 (96.6)
|
Male, n (%)
| 22 (73.3)
|
ECOG PS, n (%)
|
0-1
| 29 (96.7)
|
2
| 1 (3.3)
|
Extramedullary plasmacytomas, n (%)
|
0
| 26 (86.7)
|
≥1
| 4 (13.3)
|
ISS stagea, n (%)
|
I/II
| 27 (90)
|
III
| 3 (10)
|
Median prior LOT (range)
| 4 (2-10)
|
Refractory status, n (%)
|
Triple-classb
| 20 (66.7)
|
Penta-drugc
| 4 (13.3)
|
To last LOT
| 24 (80)
|
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; ISS, International Staging System; LOT; line of therapy; mAb, monoclonal antibody; PI, proteasome inhibitor; SUD, step-up doses. aISS staging is derived based on serum β2-microglobulin and albumin. b≥1 PI, ≥1 immunomodulatory drug, and ≥1 anti-CD38 mAb. c≥2 PIs, ≥2 immunomodulatory drugs, and ≥1 anti-CD38 mAb.
|
Efficacy
MonumenTAL-1 Study (Cohort E): Summary of Efficacy Response3
|
|
|---|
ORR, % (n/N)
| 73.3 (22/30)
|
sCR, %
| 3.3
|
CR, %
| 16.7
|
VGPR, %
| 36.7
|
PR, %
| 16.7
|
Abbreviations: CR, complete response; ORR, overall response rate; PR, partial response; sCR, stringent complete response; VGPR, very good partial response.
|
Safety
- In cohort E, CRS was reported in 15% of patients (n=3; all grade 1) who received 2 SUDs and in 50% of patients (n=5; grade 1, 30%; grade 2, 20.0%) who received 1 SUD.
- Summary of CRS events in the alternative SUD cohort E is presented in the Table: MonumenTAL-1 Study (Cohort E): Summary of CRS Events.
MonumenTAL-1 Study (Cohort E): Summary of CRS Events3
|
|
|---|
|
|
|---|
|
|
|---|
Incidence, n (%)
| 8 (40)a
| 0
|
Grade 1
| 6 (30)
| 0
|
Grade 2
| 2 (10)
| 0
|
Grade 3
| 0
| 0
|
Median time to onsetb, days (range)
| 2 (1-5)
| -
|
Median duration, days (range)
| 1 (1-38)
| -
|
During SUD1, n (%)
| 8 (40)
| 0
|
During SUD2, n (%)
| 1 (10)c
| 0
|
During SUD3, n (%)
| -
| -
|
During C1D1, n (%)
| 0
| 0
|
Recovered or resolved, n/N (%)
| 10/10 (100)
| -
|
Abbreviations: C, cycle; CRS, cytokine release syndrome; D, day; Q2W, every other week; SUD, step-up dose. aOne patient with grade 1 CRS did not receive prophylactic tocilizumab due to a pump issue. bRelative to the most recent dose. cDenominator includes only the 10 patients with 2 SUDs.
|
Patient-Reported Outcomes
- Global Health Status (GHS) and physical and emotional functioning were measured with the European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 (EORTC QLQ-C30) scales, which range from 0-100, with higher values indicating improvements.
- No apparent differences in PROs were reported between the inpatient and outpatient settings.
Morillo et al (2024)4 presented the impact of fewer SUDs on efficacy and safety, including CRS parameters, in the alternative TALVEY Q2W SUD and global TALVEY 0.8 mg/kg Q2W cohorts at a median follow-up of 6.7 months (range, 2.2-9.9).
Results
Treatment Disposition, Baseline Demographics, and Disease Characteristics
- In MonumenTAL-1, alternative SUD groups were added to the 0.8 mg/kg Q2W schedule.
- A total of 18 patients were included in this analysis to evaluate alternative TALVEY Q2W SUD regimens.
- Group 1 (n=6): week 1 SUD of TALVEY (0.03 mg/kg and 0.2 mg/kg SC); cycle 1, day 1 of TALVEY (0.8 mg/kg SC Q2W).4
- Group 2 (n=12): week 1 SUD of TALVEY (0.06 mg/kg and 0.4 mg/kg SC); cycle 1, day 1 of TALVEY (0.8 mg/kg SC Q2W).4
- Patients in both group 1 and 2 could switch to 0.8 mg/kg Q4W at confirmed partial response or better (≥PR).
- The median duration of follow-up was 6.7 months (range, 2.2-9.9).
- Most patients had high-risk cytogenetics (10/18) and were triple-class refractory (11/18), being refractory to the last LOT (11/18). Three patients had extramedullary plasmacytomas.
Efficacy
MonumenTAL-1 Study: Summary of Efficacy Response in Alternative TALVEY Q2W SUD and Global TALVEY Q2W Cohorts4
|
|
|
|---|
|
|
|---|
ORR, n (%)
| 107 (69.5)
| 5 (83.3)
| 10 (83.3)
|
sCR, %
| 31.2
| 33.3
| 25
|
CR, %
| 9.1
| -
| 16.7
|
VGPR, %
| 18.8
| 16.7
| 25
|
PR, %
| 10.4
| 33.3
| 16.7
|
≥VGPR, %
| 59.1
| 50
| 66.7
|
Median time to first response, months (range)
| -
| 1.2 (1.1-2.1)
| 1.2 (0.3-4.2)
|
Median time to best response, months (range)
| -
| 2.1 (1.1-4.7)
| 2.7 (1.1-5.5)
|
Abbreviations: CR, complete response; ORR, overall response rate; PR, partial response; Q2W, every other week; sCR, stringent complete response; SUD, step-up dose; VGPR, very good partial response. aAssessed per investigator and according to IMWG criteria.
|
Safety
CRS Incidence, Severity, Timing, and Treatment
- CRS was reported in 100% of patients (n=6) in group 1 and in 91.7% of patients (n=11) in group 2 of the alternative TALVEY Q2W SUD cohort.
- Summary of CRS events in the alternative SUD and global TALVEY Q2W cohorts is presented in the Table: MonumenTAL-1 Study: Summary of CRS Events in Alternative TALVEY Q2W SUD and Global TALVEY Q2W Cohorts.
- Incidence of CRS in the SUD phase in all 3 cohorts are presented in Table: MonumenTAL-1 Study: CRS Timing in Alternative TALVEY Q2W SUD and Global TALVEY Q2W Cohorts.
- Tocilizumab was administered for CRS in 77.8% of patients in the alternative TALVEY Q2W SUD cohort and in 37% of patients in the global TALVEY Q2W cohort. Patients who received tocilizumab did not experience any subsequent grade 2 event.
- During administration of the first SUD, 1 patient (8.3%) in group 2 experienced grade 1 neurotoxicity concurrent with CRS, which resolved without leading to TALVEY discontinuation.
- None of the patients in the alternative TALVEY Q2W SUD cohorts discontinued TALVEY due to CRS; however, 1 patient in the global TALVEY Q2W cohort discontinued TALVEY due to CRS.
Treatment Discontinuation due to other TEAEs
- No TALVEY discontinuations or deaths due to treatment-emergent adverse events (TEAEs) were reported in the alternative TALVEY Q2W SUD cohort.
MonumenTAL-1 Study: Summary of CRS Events in Alternative TALVEY Q2W SUD and Global TALVEY Q2W Cohorts4
|
|
|
|---|
|
|
|---|
Multiple CRS events, n (%)
| 51 (33.1)
| 1 (16.7)
| 3 (25)
|
Cycle with highest CRS events, SUD cycle (%)
| 2 (40.9)
| 2 (66.7)
| 1 (75)
|
CRS events during cycle 1, n
| 22
| 1
| 1
|
CRS events after cycle 2, n
| 5
| 1
| 1
|
Median time to CRS onset, days
| 2
| 2
| 2
|
Median duration of CRS, days
| 2
| 2
| 2
|
Abbreviations: CRS, cytokine release syndrome; Q2W, every other week; SUD, step-up dose. aCRS was graded by Lee et al criteria.
|
MonumenTAL-1 Study: CRS Incidence and Severity in Alternative TALVEY Q2W SUD and Global TALVEY Q2W Cohorts4
|
|
|
|---|
|
|
|---|
|
|
|
|
|
|
|
|
|
|---|
CRSb
| 57.8
| 16.2
| 0.6
| 50
| 50
| 0
| 58.3
| 33.3
| 0
|
Abbreviations: AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; CRS, cytokine release syndrome; Q2W, every other week; SUD, step-up dose. aAEs were graded per CTCAE v4.03. bCRS was graded by Lee et al criteria.
|
MonumenTAL-1 Study: CRS Timing in Alternative TALVEY Q2W SUD and Global TALVEY Q2W Cohorts4
|
|
|---|
|
|
|
|
|---|
CRSb
| 41 (26.6)
| 63 (40.9)
| 56 (36.4)
| 22 (14.3)
|
|
|
|---|
|
|
|
|
|---|
CRSb
| NA
| 3 (50)
| 4 (66.7)
| 0
|
|
|
|---|
|
|
|
|
|---|
CRSb
| NA
| 9 (75)
| 5 (41.7)
| 1 (8.3)
|
Abbreviations: AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; C1D1, cycle 1 day 1; CRS, cytokine release syndrome; NA, not applicable; Q2W, every other week; SUD, step-up dose. aAEs were graded per CTCAE v4.03. bCRS was graded by Lee et al criteria.
|
Pharmacokinetics
- As per the preliminary analysis from cycle 1 day 1 onward, talquetamab serum exposure was similar between the alternative TALVEY Q2W SUD and the global TALVEY Q2W cohorts.
- In group 1 and group 2, the median number of treatment cycles received was 10 (range, 4-11) and 5 (range, 2-10), respectively.
Literature Search
A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File databases (and/or other resources, including internal/external databases) was conducted on 12 October 2026.
| 1 | Chari A, Touzeau C, Schinke C, et al. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. Lancet Haematol. 2025;12(4):e269-e281. |
| 2 | Rasche L, Schinke C, Touzeau C, et al. Talquetamab in patients with relapsed/refractory multiple myeloma: 3-year follow-up of the phase 1/2 MonumenTAL-1 study. [published online ahead of print on August 10, 2026]. Blood. doi:10.1182/blood.2025031994. |
| 3 | Perrot A, Gatt M, Pianko MJ, et al. Prophylactic tocilizumab to mitigate cytokine release syndrome and facilitate dosing of talquetamab in all practice settings in relapsed/refractory multiple myeloma: results from MonumenTAL-1. Poster presented at: the 23rd International Myeloma Society (IMS) Annual Meeting; September 23-26, 2026; Glasgow, Scotland, UK. |
| 4 | Morillo D, Chamorro CM, Mateos MV, et al. Cytokine release syndrome in patients receiving alternative step-up doses of talquetamab for relapsed/refractory multiple myeloma: results from the phase 1/2 MonumenTAL-1 study. Poster presented at: 21st International Myeloma Society (IMS) Annual Meeting; September 25-28, 2024; Rio de Janeiro, Brazil. |
| 5 | Schinke CD, Touzeau C, Minnema MC, et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab, a GPRC5DxCD3 bispecific antibody, for relapsed/refractory multiple myeloma. Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 2-6, 2023; Chicago, IL/Virtual. |
| 6 | Jakubowiak AJ, Anguille S, Karlin L, et al. Updated results of talquetamab, a GPRC5D×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma with prior exposure to T-cell redirecting therapies: results of the phase 1/2 MonumenTAL-1 study. Poster presented at: The 65th American Society of Hematology (ASH) Annual Meeting; December 9-12, 2023; San Diego, CA/Virtual. |